Replies to post #446792 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

First time I've gotten useful info from Google's Chat Bot:

Some drugs that have been approved as part of an open-label extension (OLE) include: Radicava/Edaravone, Neudexta, Riluzole/Tiglutik.
The FDA approved Relyvrio (AMX0035) in 2022 for the treatment of ALS. Relyvrio is a combination of sodium phenylbutyrate and taurursodiol that can prevent nerve cell death by blocking stress signals.
In 2023, the FDA approved Qalsody (tofersen) for use to treat SOD1-ALS. Qalsody is the first drug developed for patients with a rare form of ALS caused by mutations in a gene called SOD1.

[bas2020]

This article might be helpful...
https://www.pbs.org/newshour/health/fda-increasingly-approves-drugs-without-conclusive-proof-they-work

More recently, Sarepta...
https://www.fiercepharma.com/pharma/after-primary-endpoint-miss-sarepta-touts-clinically-meaningful-trial-result-and-will-seek

Then there's the well-known mab fiasco for AD.

[longtermbeliever]

my adviser also told me with this trial RETT DATA should be enough to get approval.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS